Literature DB >> 32067220

Long-term deaths from melanoma according to tumor thickness at diagnosis.

Peter D Baade1, David C Whiteman2, Monika Janda3, Anne E Cust4, Rachel E Neale2,5, Bernard Mark Smithers6,7, Adele C Green2,8, Kiarash Khosrotehrani9,10, Victoria Mar11, H Peter Soyer9,10, Joanne F Aitken1,5.   

Abstract

There is little long-term follow-up information about how the number of melanoma deaths and case fatality vary over time according to the measured thickness of melanoma at diagnosis. This population-based longitudinal cohort study examines patterns and trends in case fatality among 44,531 people in Queensland (Australia) diagnosed with a single invasive melanoma (International Classification of Diseases for Oncology, third revision [ICD-O-3], C44, Morphology 872-879) between 1987 and 2011, including 11,883 diagnosed between 1987 and 1996, with up to 20 years follow-up (to December 2016). The 20-year case fatality increased by thickness, with the percentage of melanoma deaths within 20 years of diagnosis being up to 4.8% for melanomas with measured thickness <0.80 mm, 10.6% for tumors 0.8 to <1.0 mm and generally more than 30% for melanomas measuring 3 mm and more. For melanomas <1.0 mm, most deaths occurred between 5 and 20 years after diagnosis, whereas for thicker melanomas the reverse was true with most deaths occurring within the first 5 years. Five-year case fatality decreased over successive calendar time periods for melanomas <1.0 mm, but not for melanomas ≥1.0 mm. These findings demonstrate that the time course for fatal melanomas varies markedly according to tumor thickness at diagnosis. Improved understanding of the patient factors and characteristics of melanomas, in addition to tumor thickness, which increase the likelihood of progression, is needed to guide clinical diagnosis, communication with patients and ongoing surveillance pathways of patients with potentially fatal lesions.
© 2020 UICC.

Entities:  

Mesh:

Year:  2020        PMID: 32067220     DOI: 10.1002/ijc.32930

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040.

Authors:  Melina Arnold; Deependra Singh; Mathieu Laversanne; Jerome Vignat; Salvatore Vaccarella; Filip Meheus; Anne E Cust; Esther de Vries; David C Whiteman; Freddie Bray
Journal:  JAMA Dermatol       Date:  2022-05-01       Impact factor: 11.816

2.  Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence.

Authors:  Sümeyre Seda Ertekin; Sebastian Podlipnik; Constanza Riquelme-Mc Loughlin; Alicia Barreiro-Capurro; Ana Arance; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  Acta Derm Venereol       Date:  2021-07-15       Impact factor: 3.875

3.  Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial.

Authors:  Deonna M Ackermann; Amelia K Smit; Monika Janda; Cathelijne H van Kemenade; Mbathio Dieng; Rachael L Morton; Robin M Turner; Anne E Cust; Les Irwig; Jolyn K Hersch; Pascale Guitera; H Peter Soyer; Victoria Mar; Robyn P M Saw; Donald Low; Cynthia Low; Dorothy Drabarek; David Espinoza; Jon Emery; Peter Murchie; John F Thompson; Richard A Scolyer; Anthony Azzi; Alister Lilleyman; Katy J L Bell
Journal:  Trials       Date:  2021-05-04       Impact factor: 2.279

4.  Cost-effectiveness of a policy-based intervention to reduce melanoma and other skin cancers associated with indoor tanning.

Authors:  Martin Eden; Rob Hainsworth; Louisa G Gordon; Tracy Epton; Paul Lorigan; Lesley E Rhodes; Richard Marais; Adele C Green; Katherine Payne
Journal:  Br J Dermatol       Date:  2022-05-18       Impact factor: 11.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.